Ascendis Pharma (ASND) Director Jean Jacques Bienaime Buys 2,000 Shares

What Happened

• Jean Jacques Bienaime, a director of Ascendis Pharma A/S (ASND), made two open‑market purchases on August 14, 2026, acquiring a total of 2,000 shares. He bought 1,100 shares at a weighted average price of $245.85 (total ~$270,435) and 900 shares at a weighted average price of $246.91 (total ~$222,219). Total consideration for the two purchases was about $492,654. These were direct purchases (transaction code P), which are generally treated by investors as affirmative buying activity.

Key Details

• Transaction dates and prices:
  • 2026-08-14 — 1,100 shares @ weighted avg $245.85 (range $245.41–$246.30 per footnote F1) — $270,435
  • 2026-08-14 — 900 shares @ weighted avg $246.91 (range $246.48–$247.32 per footnote F2) — $222,219
• Shares owned after the transaction: not specified in the provided filing excerpt (see full Form 4 for holdings).
• Footnotes: F1 and F2 state the reported prices are weighted averages covering multiple trades and provide the per‑share price ranges; the reporting person will supply exact per‑trade counts/prices on request.
• Timeliness: Filing dated 2026-08-18 for an 2026-08-14 trade — this appears to be a timely Form 4 filing (filed within the typical 2 business‑day window).

Context

• These were straightforward open‑market purchases (no option exercises, gifts, or 10b5‑1 plan disclosed in the excerpt). Purchases by directors are often watched by retail investors as they represent direct, personal investment, but the filing itself does not state the insider’s motivation.